Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

OPTIMUNISE · Optimising the impact and cost-effectiveness of child health intervention programmes of vaccines and micronutrients in low-income countries

FP7Status: CLOSED1 March 201131 August 2016EU funding €2,999,970

International child health programmes in low-income countries are justified in term of their impact on child survival. However, the effect estimates are usually calculated from performance indicators and assumptions about efficacy based on small-scale target-specific studies. There is little follow-up of how the programmes are implemented in real life.This approach is clearly not sufficient. Recent studies have consistently shown that vaccines and micronutrients have non-specific effects, i.e. effects which are not explained by prevention of the targeted infections or deficiencies. These effects are often sex-differential. Furthermore, interventions may interact. Hence, the overall impact of child health programs can not be extrapolated from small-scale target-specific studies. There is a need to assess the real life impact and cost-effectiveness of child health intervention programmes in the context where they are being used.We propose to use health and demographic surveillance system (HDSS) sites in Africa to register information routinely on all interventions in childhood, such as all vaccinations, micronutrient supplementation, and de-worming, given at health centres or in campaigns. Using this information we will measure the overall health impact of the child health programs.The HDSS platform can also be used for testing modifications of the current health programmes. We will test a recent finding from a randomised trial in Guinea-Bissau: providing early measles vaccine at 4.5 and 9 months of age compared with the recommended measles vaccine at age 9 months reduced overall mortality from 4.5 to 36 months of age by astonishing 49%.The HDSS sites already collect data on mortality, and mortality would be the main outcome, but we also aim to identify other relevant comparable outcome parameters which correlate with mortality and which can be used to assess the overall impact of existing and new interventions.

Consortium · 8 organisations

coordinator

STATENS SERUM INSTITUT

DK · €347,280

participant

CENTRE DE RECHERCHE EN SANTE DE NOUNA

BF · €928,400

participant

INSTITUTO NACIONAL DE SAUDE PUBLICA

GW · €929,390

participant

RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU

NL · €45,000

participant

INDEPTH NETWORK

GH · €39,600

participant

UNIVERSITATSKLINIKUM HEIDELBERG

DE · €215,000

participant

GHANA HEALTH SERVICE

GH · €495,300

participant

MEDICAL RESEARCH COUNCIL

UK

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.